{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,23]],"date-time":"2026-10-23T05:32:17Z","timestamp":1792733537598,"version":"4.5.0"},"reference-count":21,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2024,11,26]],"date-time":"2024-11-26T00:00:00Z","timestamp":1732579200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100014101","name":"Novavax Inc","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100014101","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.es","clinicalkey.com.au","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.vaccine.2024.126569","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T23:47:03Z","timestamp":1733442423000},"page":"126569","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"special_numbering":"C","title":["Local and systemic reactogenicity after mRNA and protein-based COVID-19 vaccines compared to meningococcal vaccine (MenACWY) in a UK blinded, randomized phase 2 trial (COV-BOOST)"],"prefix":"10.1016","volume":"44","author":[{"given":"Anthony M.","family":"Marchese","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hadi","family":"Beyhaghi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew D.","family":"Rousculp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Huang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinxue","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Seth","family":"Toback","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Saul N.","family":"Faust","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"8","key":"10.1016\/j.vaccine.2024.126569_bb0005","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0272691","article-title":"Hesitancy and reactogenicity to mRNA-based COVID-19 vaccines\u2013early experience with vaccine rollout in a multi-site healthcare system","volume":"17","author":"Al-Obaydi","year":"2022","journal-title":"PloS One"},{"issue":"23","key":"10.1016\/j.vaccine.2024.126569_bb0010","doi-asserted-by":"crossref","first-page":"3174","DOI":"10.1016\/j.vaccine.2022.04.046","article-title":"Impact of COVID-19 vaccine-associated side effects on health care worker absenteeism and future booster vaccination","volume":"40","author":"Chrissian","year":"2022","journal-title":"Vaccine"},{"issue":"4","key":"10.1016\/j.vaccine.2024.126569_bb0015","doi-asserted-by":"crossref","first-page":"e210804","DOI":"10.1001\/jamahealthforum.2021.0804","article-title":"Fear of adverse effects and COVID-19 vaccine hesitancy: recommendations of the treatment expectation expert group","volume":"2","author":"Rief","year":"2021","journal-title":"JAMA Health Forum"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126569_bb0020","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1097\/JOM.0000000000002376","article-title":"Work absence following COVID-19 vaccination in a cohort of healthcare personnel","volume":"64","author":"Breeher","year":"2022","journal-title":"J Occup Environ Med"},{"issue":"7","key":"10.1016\/j.vaccine.2024.126569_bb0025","doi-asserted-by":"crossref","DOI":"10.1097\/MD.0000000000028839","article-title":"Are COVID-19 mRNA vaccine side effects severe enough to cause missed work? Cross-sectional study of health care-associated workers","volume":"101","author":"Cohen","year":"2022","journal-title":"Medicine"},{"key":"10.1016\/j.vaccine.2024.126569_bb0030","doi-asserted-by":"crossref","DOI":"10.3389\/fpubh.2022.929407","article-title":"Changes of factors associated with vaccine hesitancy in Chinese residents: a qualitative study","volume":"10","author":"Long","year":"2022","journal-title":"Front Public Health"},{"key":"10.1016\/j.vaccine.2024.126569_bb0035","first-page":"2023","article-title":"Older Adults\u2019 intentions and attitudes toward the updated bivalent COVID-19 booster: survey, United States, April 2023","volume":"07","author":"Costa","year":"2023","journal-title":"HealthCanal Accessed June"},{"issue":"5","key":"10.1016\/j.vaccine.2024.126569_bb0040","doi-asserted-by":"crossref","first-page":"e243","DOI":"10.1097\/INF.0000000000003499","article-title":"Effective approaches to combat vaccine hesitancy","volume":"41","author":"Tuckerman","year":"2022","journal-title":"Pediatr Infect Dis J"},{"issue":"4","key":"10.1016\/j.vaccine.2024.126569_bb0045","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2021-052335","article-title":"Parents\u2019 intentions and perceptions about COVID-19 vaccination for their children: results from a National Survey","volume":"148","author":"Szilagyi","year":"2021","journal-title":"Pediatrics"},{"issue":"5","key":"10.1016\/j.vaccine.2024.126569_bb0050","doi-asserted-by":"crossref","DOI":"10.1542\/peds.2023-062466","article-title":"COVID-19 vaccine hesitancy among parents: a qualitative study","volume":"152","author":"Honcoop","year":"2023","journal-title":"Pediatrics"},{"issue":"46","key":"10.1016\/j.vaccine.2024.126569_bb0055","doi-asserted-by":"crossref","first-page":"6680","DOI":"10.1016\/j.vaccine.2022.09.090","article-title":"COVID-19 vaccine perceptions and hesitancy amongst parents of school-aged children during the pediatric vaccine rollout","volume":"40","author":"Byrne","year":"2022","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2024.126569_bb0060","article-title":"The Novavax heterologous COVID booster demonstrates lower Reactogenicity than mRNA: a targeted review","author":"Marchese","year":"2023","journal-title":"J Infect Dis"},{"issue":"11","key":"10.1016\/j.vaccine.2024.126569_bb0065","doi-asserted-by":"crossref","first-page":"1046","DOI":"10.1056\/NEJMoa2116414","article-title":"Homologous and heterologous Covid-19 booster vaccinations","volume":"386","author":"Atmar","year":"2022","journal-title":"N Engl J Med"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126569_bb0070","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/s41541-023-00693-z","article-title":"Immunogenicity of NVX-CoV2373 heterologous boost against SARS-CoV-2 variants","volume":"8","author":"Lyke","year":"2023","journal-title":"npj Vaccines"},{"issue":"10318","key":"10.1016\/j.vaccine.2024.126569_bb0075","doi-asserted-by":"crossref","first-page":"2258","DOI":"10.1016\/S0140-6736(21)02717-3","article-title":"Safety and immunogenicity of seven COVID-19 vaccines as a third dose (booster) following two doses of ChAdOx1 nCov-19 or BNT162b2 in the UK (COV-BOOST): a blinded, multicentre, randomised, controlled, phase 2 trial","volume":"398","author":"Munro","year":"2021","journal-title":"The Lancet"},{"issue":"12","key":"10.1016\/j.vaccine.2024.126569_bb0080","doi-asserted-by":"crossref","DOI":"10.3390\/vaccines10122017","article-title":"Safety of four COVID-19 vaccines across primary doses 1, 2, 3 and booster: a prospective cohort study of Australian community pharmacy vaccinations","volume":"10","author":"Salter","year":"2022","journal-title":"Vaccines"},{"issue":"9","key":"10.1016\/j.vaccine.2024.126569_bb0085","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1080\/14760584.2022.2098719","article-title":"Comparing reactogenicity of COVID-19 vaccines: a systematic review and meta-analysis","volume":"21","author":"Sutton","year":"2022","journal-title":"Expert Rev Vaccines"},{"key":"10.1016\/j.vaccine.2024.126569_bb0090","series-title":"Package Insert - Spikevax","year":"2024"},{"issue":"2","key":"10.1016\/j.vaccine.2024.126569_bb0095","doi-asserted-by":"crossref","first-page":"167","DOI":"10.1016\/S2213-2600(21)00409-4","article-title":"Safety, immunogenicity, and efficacy of a COVID-19 vaccine (NVX-CoV2373) co-administered with seasonal influenza vaccines: an exploratory substudy of a randomised, observer-blinded, placebo-controlled, phase 3 trial","volume":"10","author":"Toback","year":"2022","journal-title":"Lancet Respir Med"},{"issue":"9","key":"10.1016\/j.vaccine.2024.126569_bb0100","doi-asserted-by":"crossref","DOI":"10.1001\/jamanetworkopen.2023.32813","article-title":"Immunogenicity and Reactogenicity of Coadministration of COVID-19 and influenza vaccines","volume":"6","author":"Gonen","year":"2023","journal-title":"JAMA Netw Open"},{"issue":"1","key":"10.1016\/j.vaccine.2024.126569_bb0105","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1186\/s12916-023-03064-6","article-title":"Patient-reported reactogenicity and safety of COVID-19 vaccinations vs. comparator vaccinations: a comparative observational cohort study","volume":"21","author":"Werner","year":"2023","journal-title":"BMC Med"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24012519?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X24012519?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2024,12,31]],"date-time":"2024-12-31T19:48:04Z","timestamp":1735674484000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X24012519"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":21,"alternative-id":["S0264410X24012519"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126569","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Local and systemic reactogenicity after mRNA and protein-based COVID-19 vaccines compared to meningococcal vaccine (MenACWY) in a UK blinded, randomized phase 2 trial (COV-BOOST)","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2024.126569","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 The Authors. Published by Elsevier Ltd.","name":"copyright","label":"Copyright"}],"article-number":"126569"}}